SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00260260

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

The Pharmacogenetics of Oxycodone Analgesia in Postoperative Pain

Patients undergoing surgery (thyroidectomy and hysterectomy) will postoperatively receive oxycodone intravenously (IV) as pain management with morphine as an escape medicine, if there is insufficient pain relief with oxycodone. Patients' pain and side effects will be registered and after 24 hours they will answer a questionnaire. All included patients will be genotyped accordingly to CYP2D6 and relevant single nucleotide polymorphisms (SNPs), and measures of plasma levels of oxycodone will be performed.

NCT00260260 Postoperative Pain
MeSH:Pain, Postoperative

1 Interventions

Name: Oxycodone

Type: Drug


Primary Outcomes

Measure: Responder (satisfaction with pain treatment in questionnaire and no escape medication)

Measure: Non-responder (dissatisfaction with pain management in questionnaire and/or escape medication)

Measure: Responder status compared to CYP2D6 genotype

Secondary Outcomes

Measure: Registration of pain, side effects and total amount of oxycodone given compared to CYP2D6 genotype and SNPs

Purpose: Treatment

Allocation: Non-Randomized

Single Group Assignment


There are 3 SNPs

SNPs


1 A118G

Among these are the A118G SNP in the μ-receptor gene OPRM1 and the C3435T and G2677T/A SNPs in the MDR-1 gene of P-glycoprotein. --- A118G ---


2 C3435T

Among these are the A118G SNP in the μ-receptor gene OPRM1 and the C3435T and G2677T/A SNPs in the MDR-1 gene of P-glycoprotein. --- A118G --- --- C3435T ---


3 G2677T

Among these are the A118G SNP in the μ-receptor gene OPRM1 and the C3435T and G2677T/A SNPs in the MDR-1 gene of P-glycoprotein. --- A118G --- --- C3435T --- --- G2677T ---



HPO Nodes